WallStSmart

Merck & Company Inc (MRK)vsSoleno Therapeutics Inc (SLNO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 22976% more annual revenue ($65.77B vs $285.01M). SLNO leads profitability with a 33.7% profit margin vs 13.6%. SLNO trades at a lower P/E of 27.4x. SLNO earns a higher WallStSmart Score of 52/100 (C-).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

SLNO

Buy

52

out of 100

Grade: C-

Growth: 4.3Profit: 9.5Value: 5.3Quality: 6.8
Piotroski: 5/9Altman Z: 1.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$120.79

$39.83 premium

UndervaluedFair: $80.96Overvalued

Intrinsic value data unavailable for SLNO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SLNO3 strengths · Avg: 9.7/10
Profit MarginProfitability
33.7%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
33.6%10/10

Strong operational efficiency at 33.6%

Return on EquityProfitability
26.4%9/10

Every $100 of equity generates 26 in profit

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SLNO4 concerns · Avg: 4.0/10
P/E RatioValuation
27.4x4/10

Moderate valuation

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.644/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SLNO

The strongest argument for SLNO centers on Profit Margin, Operating Margin, Return on Equity. Profitability is solid with margins at 33.7% and operating margin at 33.6%.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SLNO

The primary concerns for SLNO are P/E Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

MRK carries more volatility with a beta of 0.22 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SLNO scores higher overall (52/100 vs 50/100), backed by strong 33.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Soleno Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?